AI
XFOR icon

Alphabet Inc’s X4 Pharmaceuticals XFOR Stock Holding History

Alphabet Inc’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,508
Closed -$9.83M – 19
2018
Q2 		$9.83M Hold
2,508
– – 0.83% 13
2018
Q1 		$62M Hold
2,508
– – 10.08% 4
2017
Q4 		$34.6M Buy
+2,508
New +$6.34M 9.38% 3

Other funds holding XFOR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Alphabet Inc's XFOR Position: Q3 2018 in Review

Alphabet Inc sold out of X4 Pharmaceuticals (XFOR) in Q3 2018, closing a stake of 2,508 shares — an estimated $9.83M sold.

Alphabet Inc first reported a position in XFOR in Q4 2017 and held it in 3 quarters. The position peaked at $62M in Q1 2018. 40 funds tracked by Wall St. Rank hold XFOR as of Q3 2018.

  • Alphabet Inc reported no remaining X4 Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Alphabet Inc sold 2,508 X4 Pharmaceuticals shares in Q3 2018, an estimated $9.83M.
  • Alphabet Inc first reported a position in X4 Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Alphabet Inc's X4 Pharmaceuticals position peaked at $62M in Q1 2018.
  • 40 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2018.

Based on Alphabet Inc's 13F filing for Q3 2018, filed 15 Nov 2022.